Login to Your Account



Insmed prices $100M offering for Arikayce work

By Jennifer Boggs
Managing Editor

Thursday, August 14, 2014
Insmed Inc. priced a $100.1 million public offering Wednesday, more than doubling its cash balance, to support work on Arikayce, which, after yielding mixed data earlier this year, now seems poised to become the first once-daily, inhaled antibiotic for nontuberculous mycobacteria (NTM) and Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription